{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:06:09Z","timestamp":1793160369568,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jiac.2019.01.005","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T02:09:24Z","timestamp":1548900564000},"page":"351-354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Efficacies of atovaquone, pentamidine, and trimethoprim\/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2350-2922","authenticated-orcid":false,"given":"Takatoshi","family":"Kitazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3633-4243","authenticated-orcid":false,"given":"Yusuke","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurumi","family":"Asako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2019.01.005_bib1","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/cid\/ciu094","volume":"58","author":"Masur","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2019.01.005_bib2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4065\/74.7.730","article-title":"Trimethoprim-sulfamethoxazole","volume":"74","author":"Smilack","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jiac.2019.01.005_bib3","first-page":"795","article-title":"Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with wegener's granulomatosis","volume":"151","author":"Ognibene","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jiac.2019.01.005_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005590.pub2","article-title":"Prophylaxis for pneumocystis pneumonia (pcp) in non-hiv immunocompromised patients","author":"Green","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jiac.2019.01.005_bib5","doi-asserted-by":"crossref","first-page":"6730812","DOI":"10.1155\/2017\/6730812","article-title":"Incidence and risk factors for infections requiring hospitalization, including pneumocystis pneumonia, in Japanese patients with rheumatoid arthritis","volume":"2017","author":"Hashimoto","year":"2017","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.jiac.2019.01.005_bib6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.semarthrit.2011.05.004","article-title":"Primary prophylaxis for pneumocystis jirovecii pneumonia in patients with connective tissue diseases","volume":"41","author":"Vananuvat","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jiac.2019.01.005_bib7","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.11150\/kansenshogakuzasshi1970.73.1123","article-title":"Efficacy of sulfamethoxazole-trimethoprim administration in the prevention of pneumocystis carinii pneumonia in patients with connective tissue disease","volume":"73","author":"Okada","year":"1999","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.jiac.2019.01.005_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00296-007-0505-4","article-title":"Comparison of trimethoprim\u2013sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease","volume":"28","author":"Kimura","year":"2008","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jiac.2019.01.005_bib9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jiac.2019.01.005_bib10","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/j.1875-9114.1996.tb03029.x","article-title":"Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of pneumocystis carinii pneumonia","volume":"16","author":"Warnock","year":"1996","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2019.01.005_bib11","doi-asserted-by":"crossref","first-page":"E184","DOI":"10.1111\/j.1399-0012.2012.01624.x","article-title":"Atovaquone versus trimethoprim-sulfamethoxazole as pneumocystis jirovecii pneumonia prophylaxis following renal transplantation","volume":"26","author":"Gabardi","year":"2012","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jiac.2019.01.005_bib12","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJM199305273282103","article-title":"Comparison of atovaquone (566c80) with trimethoprim-sulfamethoxazole to treat pneumocystis carinii pneumonia in patients with aids","volume":"328","author":"Hughes","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2019.01.005_bib13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00002030-199202000-00004","article-title":"Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against pneumocystis carinii pneumonia in patients with aids","volume":"6","author":"Carr","year":"1992","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2019.01.005_bib14","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/sj.bmt.1702004","article-title":"A\u00a0prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim\/sulfamethoxazole as pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation","volume":"24","author":"Colby","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jiac.2019.01.005_bib15","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"Ecil guidelines for preventing pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2019.01.005_bib16","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJM199212243272603","article-title":"A\u00a0controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch aids treatment group","volume":"327","author":"Schneider","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2019.01.005_bib17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0140-6736(91)91046-W","article-title":"Adverse reactions to co-trimoxazole in hiv infection","volume":"338","author":"van der Ven","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2019.01.005_bib18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1046\/j.1537-2995.1987.27387235635.x","article-title":"Metabolite-specific (igg) and drug-specific antibodies (igg, igm) in two cases of trimethoprim-sulfamethoxazole-induced immune thrombocytopenia","volume":"27","author":"Kiefel","year":"1987","journal-title":"Transfusion"},{"key":"10.1016\/j.jiac.2019.01.005_bib19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1980.03310040042025","article-title":"Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients","volume":"244","author":"Smith","year":"1980","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.jiac.2019.01.005_bib20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/BF02599836","article-title":"Predicting cutaneous hypersensitivity reactions to cotrimoxazole in hiv-infected individuals receiving primary pneumocystis carinii pneumonia prophylaxis","volume":"10","author":"Hennessy","year":"1995","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.jiac.2019.01.005_bib21","doi-asserted-by":"crossref","first-page":"c187","DOI":"10.1159\/000328911","article-title":"Trimethoprim, creatinine and creatinine-based equations","volume":"119","author":"Delanaye","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.jiac.2019.01.005_bib22","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/jac\/dks030","article-title":"Acute kidney injury associated with trimethoprim\/sulfamethoxazole","volume":"67","author":"Fraser","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X19300200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X19300200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:58:06Z","timestamp":1761159486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X19300200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1341321X19300200"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2019.01.005","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacies of atovaquone, pentamidine, and trimethoprim\/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2019.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}